CompletedNCT03539549
A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD)
PHASE2 · 124 planned enrolment
- Countries listed
- 1
- Registry update
- August 3, 2020
Registry Intervention View
abicipar pegol
Trial registrations containing the exact intervention label abicipar pegol.
Exact registry label · Not reported
5 linked registrations
No aliases or equivalent products have been inferred.
Topics connected by trial metadata
5 linked registrations report posted results
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →Registered trials
CompletedNCT02462486
Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
PHASE3 · 949 planned enrolment
- Countries listed
- 16
- Registry update
- July 30, 2020
CompletedNCT02462928
A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
PHASE3 · 939 planned enrolment
- Countries listed
- 17
- Registry update
- July 28, 2020
CompletedNCT02181504
A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration
PHASE2 · 25 planned enrolment
- Countries listed
- 1
- Registry update
- April 25, 2017
CompletedNCT02181517
A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
PHASE2 · 25 planned enrolment
- Countries listed
- 1
- Registry update
- May 17, 2016